We also found that IFN-γ priming of patient pancreatic cancer organoids could efficiently enhance the specific recognition and killing of patient pancreatic cancer organoids by our identified HLA-A*11:01–restricted KRAS G12V–reactive TCR-transduced T cells, which highlights that patient cancer organoids can be used to test potential combination treatment approaches for TCR-gene therapy. This evidence concerns the gene KRAS and pancreatic neoplasm.